Tal Danino
Auto-generated profile, based on publicly available information

Tal Danino

Department of Biomedical Engineering, Columbia University, New York, NY, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SCSreyan Chowdhury
Sreyan Chowdhury
SCSamuel Castro
Samuel Castro
CCCourtney Coker
Courtney Coker
THTaylor E. Hinchliffe
Taylor E. Hinchliffe
NANicholas Arpaia
Nicholas Arpaia
TDTal Danino
Tal Danino

12 February 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CGCandice R. Gurbatri
Candice R. Gurbatri
ILIoana Lia
Ioana Lia
RVRosa Vincent
Rosa Vincent
CCCourtney Coker
Courtney Coker
SCSamuel Castro
Samuel Castro
TDTal Danino
Tal Danino
An engineered probiotic system locally delivers checkpoint blockade nanobodies to tumors for sustained therapeutic release.

25 November 2022 in Science
Verified
Journal Article
Closed access
CGCandice R. Gurbatri
Candice R. Gurbatri
NANicholas Arpaia
Nicholas Arpaia
TDTal Danino
Tal Danino
With increasing evidence that microbes colonize tumors, synthetic biology tools are being leveraged to repurpose bacteria as tumor-specific delivery systems. These engineered systems can modulate the tumor microenvironment using a combination of their inherent immunogenicity and local payload production. Here, we review genetic circuits that enhance spatial and temporal control of therapeutic bacteria to improve their safety and efficacy. We describe the engineering of interactions among bacteria, tumor cells, and immune cells, and the progression from bacteria as single agents toward their rational combination with other modalities. Together, these efforts are building toward an emerging concept of engineering interactions between programmable medicines using synthetic biology.

13 October 2023 in Science
Verified
Journal Article
Closed access
RVRosa L. Vincent
Rosa L. Vincent
CGCandice R. Gurbatri
Candice R. Gurbatri
FLFangda Li
Fangda Li
AVAna Vardoshvili
Ana Vardoshvili
CCCourtney Coker
Courtney Coker
TDTal Danino
Tal Danino
A major challenge facing tumor-antigen targeting therapies such as chimeric antigen receptor (CAR)–T cells is the identification of suitable targets that are specifically and uniformly expressed on heterogeneous solid tumors. By contrast, certain species of bacteria selectively colonize immune-privileged tumor cores and can be engineered as antigen-independent platforms for therapeutic delivery. To bridge these approaches, we developed a platform of probiotic-guided CAR-T cells (ProCARs), in which tumor-colonizing probiotics release synthetic targets that label tumor tissue for CAR-mediated lysis in situ. This system demonstrated CAR-T cell activation and antigen-agnostic cell lysis that was safe and effective in multiple xenograft and syngeneic models of human and mouse cancers. We further engineered multifunctional probiotics that co-release chemokines to enhance CAR-T cell recruitment and therapeutic response.

17 March 2022 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
THTetsuhiro Harimoto
Tetsuhiro Harimoto
JHJaeseung Hahn
Jaeseung Hahn
YCYu-Yu Chen
Yu-Yu Chen
JIJongwon Im
Jongwon Im
JZJoanna Zhang
Joanna Zhang
TDTal Danino
Tal Danino
Living bacteria therapies have been proposed as an alternative approach to treating a broad array of cancers. In this study, we developed a genetically encoded microbial encapsulation system with tunable and dynamic expression of surface capsular polysaccharides that enhances systemic delivery. Based on a small RNA screen of capsular biosynthesis pathways, we constructed inducible synthetic gene circuits that regulate bacterial encapsulation in Escherichia coli Nissle 1917. These bacteria are capable of temporarily evading immune attack, whereas subsequent loss of encapsulation results in effective clearance in vivo. This dynamic delivery strategy enabled a ten-fold increase in maximum tolerated dose of bacteria and improved anti-tumor efficacy in murine models of cancer. Furthermore, in situ encapsulation increased the fraction of microbial translocation among mouse tumors, leading to efficacy in distal tumors. The programmable encapsulation system promises to enhance the therapeutic utility of living engineered bacteria for cancer.

16 October 2024 in Nature
Verified
Journal Article
Open access
PDF file
ARAndrew Redenti
Andrew Redenti
JIJongwon Im
Jongwon Im
BRBenjamin Redenti
Benjamin Redenti
FLFangda Li
Fangda Li
MRMathieu Rouanne
Mathieu Rouanne
NANicholas Arpaia
Nicholas Arpaia
Microbial systems have been synthetically engineered to deploy therapeutic payloads in vivo1,2. With emerging evidence that bacteria naturally home in on tumours3,4 and modulate antitumour immunity5,6, one promising application is the development of bacterial vectors as precision cancer vaccines2,7. Here we engineered probiotic Escherichia coli Nissle 1917 as an antitumour vaccination platform optimized for enhanced production and cytosolic delivery of neoepitope-containing peptide arrays, with increased susceptibility to blood clearance and phagocytosis. These features enhance both safety and immunogenicity, achieving a system that drives potent and specific T cell-mediated anticancer immunity that effectively controls or eliminates tumour growth and extends survival in advanced murine primary and metastatic solid tumours. We demonstrate that the elicited antitumour immune response involves recruitment and activation of dendritic cells, extensive priming and activation of neoantigen-specific CD4+ and CD8+ T cells, broader activation of both T and natural killer cells, and a reduction of tumour-infiltrating immunosuppressive myeloid and regulatory T and B cell populations. Taken together, this work leverages the advantages of living medicines to deliver arrays of tumour-specific neoantigen-derived epitopes within the optimal context to induce specific, effective and durable systemic antitumour immunity.